An Alternative Radiation Fractionation Strategy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Status unconfirmed · Phase 1
Conditions studied: Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
In brief
This phase I trial studies the best dose of radiation therapy in treating patients with locally advanced non-small cell lung cancer that cannot be removed by surgery. Radiation therapy uses high energy x rays to kill tumor cells. Specialized radiation therapy, such as stereotactic body radiation therapy (SBRT), that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. SBRT has been shown to provide excellent results when used in early stage lung cancer, but has not yet been applied to patients with more advanced disease.
Key facts
- Study ID
- NCT01711697
- Run by
- Emory University
- People needed
- 16
- Starts
- 2012-09-04
- Expected to finish
- 2022-05-31
- Last updated by the study team
- 2021-06-23
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Biopsy proven NSCLC, within 8 weeks prior to patient registration
- Unresectable disease
- Clinical stage Tx, T1-T4, N1-3, M0
- Karnofsky performance status (KPS) ≥ 70
- Pretreatment positron emission tomography (PET) CT scan to rule out metastatic disease
- The primary tumor may not be larger than 8 cm in maximum dimension
- If the primary tumor is central in location, defined as within 2 cm from the tracheobronchial tree, it must be no larger than 5 cm
- Mediastinal and hilar lymphadenopathy can be no larger than 5 cm at any nodal station
- Pretreatment brain CT with contrast or brain MRI to rule out metastases
- Pathologic assessment of the mediastinum to document involved nodal stations
- All of the above inclusion criteria must occur within 8 weeks prior to patient registration, with the exception of pathologic assessment of the mediastinum and biopsy to confirm NSCLC, which can be done within 12 weeks of patient registration
You may not qualify if…
- Prior history of lung cancer
- Pregnancy
- Prior history of radiation to the chest
Where it is running
- Grady Health System — Atlanta, Georgia, United States
- Emory University Hospital Midtown — Atlanta, Georgia, United States
- Emory University Winship Cancer Institute — Atlanta, Georgia, United States
- Siteman Cancer Center - Washington University — St Louis, Missouri, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.